The emergence of drugs like copyright and Semaglutide signifies a major shift in how we approach type 2 diabetes. These groundbreaking therapies belong to a class known as GLP-1 target agonists, which replicate the effects of a natural hormone that controls sugar levels and appetite. Initially, d